Global Custom Market Research Reports Provider Company

phone

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review

  • Published Date: 11 Jul 2018
  • Number of Pages: 66
  • Category: SWOT Analysis
  • Country: United States of America
Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies and liver targeted pro-drug technologies to assist companies in securing prescription drug approvals. It provides a diversified portfolio of biotechnology and pharmaceutical products for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc Key Recent Developments

May 08,2018: Ligand Reports First Quarter 2018 Financial Results May 8, 2018
Feb 21,2018: Ligand Reports Fourth Quarter and Full Year 2017 Financial Results
Nov 09,2017: Ligand Reports Third Quarter 2017 Financial Results
Aug 29,2017: ImmunoPrecise announces R&D success using the OmniAb platform to develop fully human antibodies
Aug 21,2017: Ligand Appoints Dr. Nancy Gray to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData


List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Ligand Pharmaceuticals Inc - Key Facts 6
Ligand Pharmaceuticals Inc - Key Employees 7
Ligand Pharmaceuticals Inc - Key Employee Biographies 8
Ligand Pharmaceuticals Inc - Major Products and Services 9
Ligand Pharmaceuticals Inc - History 13
Ligand Pharmaceuticals Inc - Company Statement 18
Ligand Pharmaceuticals Inc - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Section 2 Company Analysis 21
Company Overview 21
Ligand Pharmaceuticals Inc - Business Description 22
Ligand Pharmaceuticals Inc - Corporate Strategy 23
Ligand Pharmaceuticals Inc - SWOT Analysis 24
SWOT Analysis - Overview 24
Ligand Pharmaceuticals Inc - Strengths 24
Ligand Pharmaceuticals Inc - Weaknesses 25
Ligand Pharmaceuticals Inc - Opportunities 26
Ligand Pharmaceuticals Inc - Threats 27
Ligand Pharmaceuticals Inc - Key Competitors 28
Section 3 Company Financial Ratios 29
Financial Ratios - Capital Market Ratios 29
Financial Ratios - Annual Ratios 30
Performance Chart 33
Financial Performance 33
Financial Ratios - Interim Ratios 34
Financial Ratios - Ratio Charts 35
Section 4 Companys Lifesciences Financial Deals and Alliances 36
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37
Ligand Pharmaceuticals Inc, Recent Deals Summary 38
Section 5 Companys Recent Developments 39
May 08, 2018: Ligand Reports First Quarter 2018 Financial Results May 8, 2018 39
Feb 21, 2018: Ligand Reports Fourth Quarter and Full Year 2017 Financial Results 42
Nov 09, 2017: Ligand Reports Third Quarter 2017 Financial Results 45
Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb platform to develop fully human antibodies 48
Aug 21, 2017: Ligand Appoints Dr. Nancy Gray to its Board of Directors 49
Aug 07, 2017: Ligand Reports Second Quarter 2017 Financial Results 50
May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 53
Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 56
Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 58
Feb 14, 2017: Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform 61
Section 6 Appendix 62
Methodology 62
Ratio Definitions 62
About GlobalData 66
Contact Us 66
Disclaimer 66

List Of Tables

List of Tables
Ligand Pharmaceuticals Inc, Key Facts 6
Ligand Pharmaceuticals Inc, Key Employees 7
Ligand Pharmaceuticals Inc, Key Employee Biographies 8
Ligand Pharmaceuticals Inc, Major Products and Services 9
Ligand Pharmaceuticals Inc, History 13
Ligand Pharmaceuticals Inc, Subsidiaries 19
Ligand Pharmaceuticals Inc, Key Competitors 28
Ligand Pharmaceuticals Inc, Ratios based on current share price 29
Ligand Pharmaceuticals Inc, Annual Ratios 30
Ligand Pharmaceuticals Inc, Annual Ratios (Cont...1) 31
Ligand Pharmaceuticals Inc, Annual Ratios (Cont...2) 32
Ligand Pharmaceuticals Inc, Interim Ratios 34
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37
Ligand Pharmaceuticals Inc, Recent Deals Summary 38
Currency Codes 62
Capital Market Ratios 62
Equity Ratios 63
Profitability Ratios 63
Cost Ratios 64
Liquidity Ratios 64
Leverage Ratios 65
Efficiency Ratios 65

List Of Figures

List of Figures
Ligand Pharmaceuticals Inc, Performance Chart (2013 - 2017) 33
Ligand Pharmaceuticals Inc, Ratio Charts 35
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 37

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

View Report

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Pipeline

View Report

Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Pipeline

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports